Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,33746741,half-maximal inhibitory concentration,"The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 μM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,8.79,5916,DB00514,Dextromethorphan
,33746741,half-maximal inhibitory concentration,"The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 μM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,20.17,5917,DB00514,Dextromethorphan
,33746741,Ki,"Poziotinib was a competitive inhibitor of cyp2b1 and cyp2c11, with Ki values of 16.18 and 17.66 μM, respectively.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,16.18,5918,DB00514,Dextromethorphan
,33746741,Ki,"Poziotinib was a competitive inhibitor of cyp2b1 and cyp2c11, with Ki values of 16.18 and 17.66 μM, respectively.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,17.66,5919,DB00514,Dextromethorphan
,9109178,haloperidol/haloperidol ratios,"Ten patients who experienced extrapyramidal side effects had higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios than the other patients (2.49 +/- 1.42 [S.D.] ng/ml vs. 1.10 +/- 0.46 ng/ml, P = 0.014 and 0.287 +/- 0.102 vs. 0.192 +/- 0.065, P = 0.030).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),,0.287,10385,DB00514,Dextromethorphan
,9109178,haloperidol/haloperidol ratios,"Ten patients who experienced extrapyramidal side effects had higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios than the other patients (2.49 +/- 1.42 [S.D.] ng/ml vs. 1.10 +/- 0.46 ng/ml, P = 0.014 and 0.287 +/- 0.102 vs. 0.192 +/- 0.065, P = 0.030).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),,0.192,10386,DB00514,Dextromethorphan
,9109178,concentrations,"The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 +/- 2.91 ng/ml vs. 5.83 +/- 1.79 ng/ml, P = 0.066 and 0.023 +/- 0.017 vs. 0.011 +/- 0.010, P = 0.077).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),ng,8,10387,DB00514,Dextromethorphan
,9109178,concentrations,"The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 +/- 2.91 ng/ml vs. 5.83 +/- 1.79 ng/ml, P = 0.066 and 0.023 +/- 0.017 vs. 0.011 +/- 0.010, P = 0.077).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),[ng] / [ml],5.83,10388,DB00514,Dextromethorphan
,9109178,concentrations,"The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 +/- 2.91 ng/ml vs. 5.83 +/- 1.79 ng/ml, P = 0.066 and 0.023 +/- 0.017 vs. 0.011 +/- 0.010, P = 0.077).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),,0.023,10389,DB00514,Dextromethorphan
,9109178,concentrations,"The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 +/- 2.91 ng/ml vs. 5.83 +/- 1.79 ng/ml, P = 0.066 and 0.023 +/- 0.017 vs. 0.011 +/- 0.010, P = 0.077).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),,0.011,10390,DB00514,Dextromethorphan
,2376428,peak concentration,"The peak concentration of dextrorphan was achieved at 1.5 h after Extuson and at 2 h after Redol comp (1,053.0 +/- 366.5 ng/ml and 901.5 +/- 210.9 ng/ml, NS).",Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),[ng] / [ml],"1,053.0",10895,DB00514,Dextromethorphan
,2376428,peak concentration,"The peak concentration of dextrorphan was achieved at 1.5 h after Extuson and at 2 h after Redol comp (1,053.0 +/- 366.5 ng/ml and 901.5 +/- 210.9 ng/ml, NS).",Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),[ng] / [ml],901.5,10896,DB00514,Dextromethorphan
,2376428,AUC0-12,"AUC0-12 values of dextrorphan were 4,315.6 +/- 295.0 (ng/ml)h after Extuson and 3,983.8 +/- 205.6 (ng/ml)h after Redol comp (p less than 0.05).",Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),h,"4,315.6",10897,DB00514,Dextromethorphan
,2376428,AUC0-12,"AUC0-12 values of dextrorphan were 4,315.6 +/- 295.0 (ng/ml)h after Extuson and 3,983.8 +/- 205.6 (ng/ml)h after Redol comp (p less than 0.05).",Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),h,"3,983.8",10898,DB00514,Dextromethorphan
,2376428,peak concentration,Salbutamol was well absorbed from the combined preparation and the peak concentration was achieved at 3 h (6.57 +/- 2.95 ng/ml).,Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),[ng] / [ml],6.57,10899,DB00514,Dextromethorphan
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,8.53,11633,DB00514,Dextromethorphan
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,6.69,11634,DB00514,Dextromethorphan
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,4.35,11635,DB00514,Dextromethorphan
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,8.67,11636,DB00514,Dextromethorphan
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,13.02,11637,DB00514,Dextromethorphan
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,14.78,11638,DB00514,Dextromethorphan
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,234.9,11639,DB00514,Dextromethorphan
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,525.4,11640,DB00514,Dextromethorphan
,15303659,recovery,"The within-day and between-day RSD were less than 12.4%, and the average recovery was between 97.3% - 109.4%.",[Simultaneous determination of pseudoephedrine and chlorpheniramine in human plasma by HPLC-UV detection method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15303659/),%,97.3,14290,DB00514,Dextromethorphan
,15303659,recovery,"The within-day and between-day RSD were less than 12.4%, and the average recovery was between 97.3% - 109.4%.",[Simultaneous determination of pseudoephedrine and chlorpheniramine in human plasma by HPLC-UV detection method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15303659/),%,109.4,14291,DB00514,Dextromethorphan
,16280263,flow-rate,"The mobile phase consisted of acetonitrile-water-formic acid (34:66:1, v/v/v), and flow-rate was 0.5 ml min(-1).",Identification and quantitative determination of benproperine metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280263/),[ml] / [min],0.5,15791,DB00514,Dextromethorphan
,11259989,terminal half-life,The terminal half-life of sabeluzole was significantly prolonged in subjects with severe hepatic dysfunction vs healthy subjects (respectively 39.3 +/- 11.5 h; 17.5 +/- 10.2 h (mean +/- s.d.)).,Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259989/),h,39.3,20751,DB00514,Dextromethorphan
,11259989,terminal half-life,The terminal half-life of sabeluzole was significantly prolonged in subjects with severe hepatic dysfunction vs healthy subjects (respectively 39.3 +/- 11.5 h; 17.5 +/- 10.2 h (mean +/- s.d.)).,Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259989/),h,17.5,20752,DB00514,Dextromethorphan
,11259989,areas under the curve (AUC),The areas under the curve (AUC) were significantly higher in subjects with severe hepatic dysfunction than in healthy volunteers (681 +/- 200 ng ml(-1) h vs 331 +/- 282 ng ml(-1) h).,Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259989/),[h·ng] / [ml],681,20753,DB00514,Dextromethorphan
,11259989,areas under the curve (AUC),The areas under the curve (AUC) were significantly higher in subjects with severe hepatic dysfunction than in healthy volunteers (681 +/- 200 ng ml(-1) h vs 331 +/- 282 ng ml(-1) h).,Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259989/),[h·ng] / [ml],331,20754,DB00514,Dextromethorphan
,32215046,flow rate,"The chromatographic separation was performed on a Waters XBridge™ C18 column (2.1 mm × 100 mm, 3.5 μm) using a gradient elution with the mobile phase consisting of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.3 mL/min.",HPLC-MS/MS Analysis of Aconiti Lateralis Radix Praeparata and Its Combination with Red Ginseng Effect on Rat CYP450 Activities Using the Cocktail Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32215046/),[ml] / [min],0.3,20924,DB00514,Dextromethorphan
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],510,21188,DB00514,Dextromethorphan
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],320,21189,DB00514,Dextromethorphan
,1771652,half-life,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),h,120,21190,DB00514,Dextromethorphan
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.55,21191,DB00514,Dextromethorphan
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.79,21192,DB00514,Dextromethorphan
,12412819,C(max),"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[ng] / [ml],19,21697,DB00514,Dextromethorphan
,12412819,C(max),"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[ng] / [ml],36,21698,DB00514,Dextromethorphan
,12412819,AUC0-infinity,"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[h·ng] / [ml],482,21699,DB00514,Dextromethorphan
,12412819,AUC0-infinity,"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[h·ng] / [ml],2383,21700,DB00514,Dextromethorphan
,11673747,oral clearance,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,121.8,21797,DB00514,Dextromethorphan
,11673747,oral clearance,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,254.5,21798,DB00514,Dextromethorphan
,11673747,oral bioavailability,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,0.28,21799,DB00514,Dextromethorphan
,11673747,oral bioavailability,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,0.17,21800,DB00514,Dextromethorphan
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],283.7,23877,DB00514,Dextromethorphan
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],295.7,23878,DB00514,Dextromethorphan
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23879,DB00514,Dextromethorphan
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23880,DB00514,Dextromethorphan
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],292.0,23881,DB00514,Dextromethorphan
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23882,DB00514,Dextromethorphan
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],424.9,23883,DB00514,Dextromethorphan
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23884,DB00514,Dextromethorphan
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],595.3,23885,DB00514,Dextromethorphan
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],760.6,23886,DB00514,Dextromethorphan
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],788.7,23887,DB00514,Dextromethorphan
,30788337,dose-normalized AUC 0-24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[h·ng] / [ml],1176,25165,DB00514,Dextromethorphan
,30788337,dose-normalized AUC 0-24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[h·ng] / [ml],791,25166,DB00514,Dextromethorphan
,30788337,dose-normalized AUC 0-24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[h·ng] / [ml],473,25167,DB00514,Dextromethorphan
,30788337,C24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[ng] / [ml],32.7,25168,DB00514,Dextromethorphan
,30788337,C24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[ng] / [ml],20.1,25169,DB00514,Dextromethorphan
,30788337,C24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[ng] / [ml],12.8,25170,DB00514,Dextromethorphan
,15491104,flow-rate,"The mobile phase consisted of methanol-water-formic acid (70:30:1), at a flow-rate of 0.5 mL x min(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),[ml] / [min],0.5,27108,DB00514,Dextromethorphan
,15491104,Tmax,"Pharmacokinetic parameters of dextrorphan was obtained as follows: Tmax was (2.1 +/- 0.7) h, Cmax was (14 +/- 8) microg x L(-1), T1/2 was (3.8 +/- 1.8) h, AUC0-t was (60 +/- 37) microg x h x L(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),h,2.1,27109,DB00514,Dextromethorphan
,15491104,Cmax,"Pharmacokinetic parameters of dextrorphan was obtained as follows: Tmax was (2.1 +/- 0.7) h, Cmax was (14 +/- 8) microg x L(-1), T1/2 was (3.8 +/- 1.8) h, AUC0-t was (60 +/- 37) microg x h x L(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),[μg] / [l],14,27110,DB00514,Dextromethorphan
,15491104,T1/2,"Pharmacokinetic parameters of dextrorphan was obtained as follows: Tmax was (2.1 +/- 0.7) h, Cmax was (14 +/- 8) microg x L(-1), T1/2 was (3.8 +/- 1.8) h, AUC0-t was (60 +/- 37) microg x h x L(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),h,3.8,27111,DB00514,Dextromethorphan
,15491104,AUC0-t,"Pharmacokinetic parameters of dextrorphan was obtained as follows: Tmax was (2.1 +/- 0.7) h, Cmax was (14 +/- 8) microg x L(-1), T1/2 was (3.8 +/- 1.8) h, AUC0-t was (60 +/- 37) microg x h x L(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),[h·μg] / [l],60,27112,DB00514,Dextromethorphan
,7875642,apparent elimination half-life,"In healthy volunteers, nefazodone was rapidly absorbed after which the plasma concentrations declined with an apparent elimination half-life ranging from 2.7 +/- 1.7 h to 10.2 +/- 4.4 h according to the dosage.",Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),h,2.7,30564,DB00514,Dextromethorphan
,7875642,apparent elimination half-life,"In healthy volunteers, nefazodone was rapidly absorbed after which the plasma concentrations declined with an apparent elimination half-life ranging from 2.7 +/- 1.7 h to 10.2 +/- 4.4 h according to the dosage.",Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),h,10.2,30565,DB00514,Dextromethorphan
,7875642,half-life,"Hydroxy-nefazodone appeared rapidly in plasma and its time-course (half-life ranging 1.4 +/- 0.9 h to 6.5 +/- 1.6 h) paralleled that of nefazodone, while mCPP showed low and variable concentrations.",Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),h,1.4,30566,DB00514,Dextromethorphan
,7875642,half-life,"Hydroxy-nefazodone appeared rapidly in plasma and its time-course (half-life ranging 1.4 +/- 0.9 h to 6.5 +/- 1.6 h) paralleled that of nefazodone, while mCPP showed low and variable concentrations.",Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),h,6.5,30567,DB00514,Dextromethorphan
,7875642,molar AUC0-48,The constant molar AUC0-48 hydroxy-nefazodone/nefazodone ratio (0.32 +/- 0.04) and the close correlation (r2 = 0.95) between kinetic parameters of nefazodone and hydroxy-nefazodone suggest that nefazodone hydroxylation is not a saturable process.,Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),,0.32,30568,DB00514,Dextromethorphan
,32285669,area under the time-concentration curves,"The observed area under the time-concentration curves were unaffected, except for alprazolam which decreased 7.6% (564.6 ± 46.1 h·μg/L pre-hop and 521.9 ± 36.1 h·μg/L post-hop; p-value 0.047), suggesting minor induction of CYP3A4/5.",Pharmacokinetic Interactions of a Hop Dietary Supplement with Drug Metabolism in Perimenopausal and Postmenopausal Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32285669/),[h·μg] / [l],564.6,35551,DB00514,Dextromethorphan
,32285669,area under the time-concentration curves,"The observed area under the time-concentration curves were unaffected, except for alprazolam which decreased 7.6% (564.6 ± 46.1 h·μg/L pre-hop and 521.9 ± 36.1 h·μg/L post-hop; p-value 0.047), suggesting minor induction of CYP3A4/5.",Pharmacokinetic Interactions of a Hop Dietary Supplement with Drug Metabolism in Perimenopausal and Postmenopausal Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32285669/),[h·μg] / [l],521.9,35552,DB00514,Dextromethorphan
,7742159,minimum plasma concentration,There was a nine-fold variation in the minimum plasma concentration of codeine consistent with pain relief (40-350 ng ml-1).,Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742159/),[ng] / [ml],40-350,41394,DB00514,Dextromethorphan
,24254834,flow rate,"Three analytes were extracted from plasma by liquid-liquid extraction using ethyl acetate and separated on a Kromasil 60-5CN column (3 µm, 2.1 × 150 mm) with mobile phase of acetonitrile-water (containing 0.1% formic acid; 50:50, v/v) at a flow rate of 0.2 mL/min.","Simultaneous quantitative analysis of dextromethorphan, dextrorphan and chlorphenamine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24254834/),[ml] / [min],0.2,41652,DB00514,Dextromethorphan
,23881421,metabolic ratio,"The mean metabolic ratio (± standard deviation) before and after GSE supplementation was 0.41 (± 0.56) and 0.48 (± 0.59), respectively.",The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23881421/),,0.41,43813,DB00514,Dextromethorphan
,23881421,metabolic ratio,"The mean metabolic ratio (± standard deviation) before and after GSE supplementation was 0.41 (± 0.56) and 0.48 (± 0.59), respectively.",The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23881421/),,0.48,43814,DB00514,Dextromethorphan
,22147075,Terminal elimination half-life (t (1/2)),Terminal elimination half-life (t (1/2)) was 51.4 h.,The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147075/),h,51.4,46991,DB00514,Dextromethorphan
,19033124,flow rate,"The Agilent ZORBAX SB-C18 (3.5 microm,2.1 x 150 mm) was used as the analytical column with acetonitrile-NH4AC buffer (70:30, V/V) as the mobile phase at the flow rate of 0.3 ml/min.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),[ml] / [min],0.3,52426,DB00514,Dextromethorphan
,19033124,m,"The sample was ionized by electrospray ionization source in the triple quadruple tandem mass spectrometer, and the plasma escitalopram determined with a multiple reaction monitoring mode of m/z325.4-->109.4.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),,325.4,52427,DB00514,Dextromethorphan
,19033124,m,"The sample was ionized by electrospray ionization source in the triple quadruple tandem mass spectrometer, and the plasma escitalopram determined with a multiple reaction monitoring mode of m/z325.4-->109.4.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),,109.4,52428,DB00514,Dextromethorphan
,19033124,absolute recovery,"The linear range was 0.0866-64.13 microg/L (r=0.9965) for escitalopram in human plasma, with the absolute recovery between 64.98% and 78.72% and the within-day and between-day deviations less than 10%.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),%,64.98,52429,DB00514,Dextromethorphan
,19033124,absolute recovery,"The linear range was 0.0866-64.13 microg/L (r=0.9965) for escitalopram in human plasma, with the absolute recovery between 64.98% and 78.72% and the within-day and between-day deviations less than 10%.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),%,78.72,52430,DB00514,Dextromethorphan
,734214,limit of sensitivity,Employing tritium labelled-DM as the radioligand the RIA had a limit of sensitivity of about 4 ng/ml of plasma using a 0.5 ml sample.,Dextromethorphan: radioimmunoassay and pharmacokinetics in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/734214/),[ng] / [ml],4,53171,DB00514,Dextromethorphan
,734214,half-life,"Following I.V. administration of 2 mg/kg of DM to two dogs, the plasma levels of intact DM declined biexponentially; the terminal exponential phase having a half-life of 2.5-3.9 hr.",Dextromethorphan: radioimmunoassay and pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/734214/),h,2.5-3.9,53172,DB00514,Dextromethorphan
,734214,volume of distribution of the central compartment,The volume of distribution of the central compartment ranged from 5-6.4 l/kg while the metabolic clearance rate ranged from 2.5-2.6 1/hr/kg.,Dextromethorphan: radioimmunoassay and pharmacokinetics in the dog. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/734214/),[l] / [kg],5-6.4,53173,DB00514,Dextromethorphan
,734214,metabolic clearance rate,The volume of distribution of the central compartment ranged from 5-6.4 l/kg while the metabolic clearance rate ranged from 2.5-2.6 1/hr/kg.,Dextromethorphan: radioimmunoassay and pharmacokinetics in the dog. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/734214/),[1] / [h·kg],2.5-2.6,53174,DB00514,Dextromethorphan
,734214,peak plasma levels,Oral administration of 10 mg/kg of DM in gelatin capsule resulted in peak plasma levels of 50 and 92 ng/ml at 2 hr post-drug.,Dextromethorphan: radioimmunoassay and pharmacokinetics in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/734214/),[ng] / [ml],50,53175,DB00514,Dextromethorphan
,734214,peak plasma levels,Oral administration of 10 mg/kg of DM in gelatin capsule resulted in peak plasma levels of 50 and 92 ng/ml at 2 hr post-drug.,Dextromethorphan: radioimmunoassay and pharmacokinetics in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/734214/),[ng] / [ml],92,53176,DB00514,Dextromethorphan
,10678105,Cl,"The Cl of Pro enantiomers in IM group was only about half of that in VEM group [(67 +/- 17) vs (133 +/- 28) L.h-1 for S-Pro, (90 +/- 24) vs (200 +/- 87) L.h-1 for R-Pro, P < 0.01].",CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678105/),[l] / [h],67,54742,DB00514,Dextromethorphan
,10678105,Cl,"The Cl of Pro enantiomers in IM group was only about half of that in VEM group [(67 +/- 17) vs (133 +/- 28) L.h-1 for S-Pro, (90 +/- 24) vs (200 +/- 87) L.h-1 for R-Pro, P < 0.01].",CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678105/),[l] / [h],133,54743,DB00514,Dextromethorphan
,10678105,Cl,"The Cl of Pro enantiomers in IM group was only about half of that in VEM group [(67 +/- 17) vs (133 +/- 28) L.h-1 for S-Pro, (90 +/- 24) vs (200 +/- 87) L.h-1 for R-Pro, P < 0.01].",CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678105/),[l] / [h],90,54744,DB00514,Dextromethorphan
,10678105,Cl,"The Cl of Pro enantiomers in IM group was only about half of that in VEM group [(67 +/- 17) vs (133 +/- 28) L.h-1 for S-Pro, (90 +/- 24) vs (200 +/- 87) L.h-1 for R-Pro, P < 0.01].",CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678105/),[l] / [h],200,54745,DB00514,Dextromethorphan
,17523762,half-life,"Following IV infusion, the steady-state plasma concentration (C(ss)) for repinotan was reached after 4-6 hours consistent with its half-life of 0.8-1.8 hours.",Effect of gender and age on the pharmacokinetics of repinotan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523762/),h,0.8-1.8,59967,DB00514,Dextromethorphan
,14663456,area under the plasma alprazolam concentration versus time curve,The area under the plasma alprazolam concentration versus time curve was 476 +/- 178 h. ng. mL(-1) at baseline and 479 +/- 125 h.,Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663456/),[h·ng] / [ml],476,61635,DB00514,Dextromethorphan
,14663456,area under the plasma alprazolam concentration versus time curve,The area under the plasma alprazolam concentration versus time curve was 476 +/- 178 h. ng. mL(-1) at baseline and 479 +/- 125 h.,Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663456/),h,479,61636,DB00514,Dextromethorphan
,14663456,elimination half-life,"The elimination half-life of alprazolam was 11.4 +/- 3.1 hours at baseline and 11.6 +/- 2.7 hours after saw palmetto treatment (P =.770, NS), also indicating a lack of effect on CYP3A4 activity.",Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663456/),h,11.4,61637,DB00514,Dextromethorphan
,14663456,elimination half-life,"The elimination half-life of alprazolam was 11.4 +/- 3.1 hours at baseline and 11.6 +/- 2.7 hours after saw palmetto treatment (P =.770, NS), also indicating a lack of effect on CYP3A4 activity.",Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663456/),h,11.6,61638,DB00514,Dextromethorphan
,10391422,metabolic ratios,All subjects were extensive metabolizers of CYP2D6 as determined by metabolic ratios of DM:DT (mean+/-SD 0.0255+/-0.048).,A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391422/),,0,62218,DB00514,Dextromethorphan
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,22.48,65057,DB00514,Dextromethorphan
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,18.34,65058,DB00514,Dextromethorphan
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,3.62,65059,DB00514,Dextromethorphan
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,3.68,65060,DB00514,Dextromethorphan
,9174682,areas under the serum concentration-time curve,Poor metabolizers of dextromethorphan had significantly higher areas under the serum concentration-time curve than extensive metabolizers of dextromethorphan (mean 1.31 vs 1.00 mumol.h.l-1).,Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174682/),[h·μM] / [l],1.31,72340,DB00514,Dextromethorphan
,9174682,areas under the serum concentration-time curve,Poor metabolizers of dextromethorphan had significantly higher areas under the serum concentration-time curve than extensive metabolizers of dextromethorphan (mean 1.31 vs 1.00 mumol.h.l-1).,Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174682/),[h·μM] / [l],1.00,72341,DB00514,Dextromethorphan
,13129991,elimination half-life,Alprazolam elimination half-life was shortened from a mean (SD) of 12.4 (3.9) hours to 6.0 (2.4) hours (P<.001).,Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/13129991/),h,12.4,74148,DB00514,Dextromethorphan
,13129991,elimination half-life,Alprazolam elimination half-life was shortened from a mean (SD) of 12.4 (3.9) hours to 6.0 (2.4) hours (P<.001).,Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/13129991/),h,6.0,74149,DB00514,Dextromethorphan
,1623909,total plasma clearance,Codeine had a medium to high extraction ratio and a total plasma clearance of 10.8 (4.3) ml.min-1.kg-1.,The postoperative pharmacokinetics of codeine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623909/),[ml] / [kg·min],10.8,75152,DB00514,Dextromethorphan
,1623909,systemic availability,The systemic availability of codeine varied extensively between subjects (range 12-84%).,The postoperative pharmacokinetics of codeine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623909/),%,12-84,75153,DB00514,Dextromethorphan
,14531724,elimination half-life,"The elimination half-life of linezolid is 5-7 hours, and twice-daily administration of 400-600 mg provides steady-state concentrations in the therapeutic range.","Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531724/),h,5-7,79676,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.95,81454,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.01,81455,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.97,81456,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81457,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.36,81458,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.90,81459,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.79,81460,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81461,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.66,81462,DB00514,Dextromethorphan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.90,81463,DB00514,Dextromethorphan
,8963481,absolute bioavailability,"There was a 21% absolute bioavailability of levomepromazine, indicating a pronounced presystemic metabolism.",Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8963481/),%,21,82629,DB00514,Dextromethorphan
,8963481,total serum clearance,"The total serum clearance and the apparent volume of distribution at steady state were 48 +/- 14 l/min and 980 +/- 213 l, respectively.",Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8963481/),[l] / [min],48,82630,DB00514,Dextromethorphan
,8963481,apparent volume of distribution at steady state,"The total serum clearance and the apparent volume of distribution at steady state were 48 +/- 14 l/min and 980 +/- 213 l, respectively.",Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8963481/),l,980,82631,DB00514,Dextromethorphan
,7520903,half-life,In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers.,The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,19,83624,DB00514,Dextromethorphan
,7520903,half-life,In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers.,The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,3,83625,DB00514,Dextromethorphan
,7520903,half-life,"However, becuase the pharmacology of 9-hydroxyrisperidone is very similar to that of risperidone, the half-life for the ""active fraction"" (risperidone +9-hydroxyrisperidone) was found to be approximately 20 hours in extensive and poor metabolizers.",The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,20,83626,DB00514,Dextromethorphan
,9840216,relative bioavailability,The relative bioavailability of the tablet dosage form with respect to the suspension was found to be 113% on Day 1 and 110% on Day 6.,Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840216/),%,113,84582,DB00514,Dextromethorphan
,9840216,relative bioavailability,The relative bioavailability of the tablet dosage form with respect to the suspension was found to be 113% on Day 1 and 110% on Day 6.,Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840216/),%,110,84583,DB00514,Dextromethorphan
,9797797,Peak serum concentrations,Peak serum concentrations of selegiline were reached rapidly and ranged from 1 to 32 nmol/L.,CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[nM] / [l],1 to 32,84693,DB00514,Dextromethorphan
,9797797,50% inhibitory concentration,"The inhibitory potency of selegiline, desmethylselegiline, and l-methamphetamine toward dextromethorphan O-demethylase was very low (50% inhibitory concentration values from 160 to 580 mumol/L).",CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[μM] / [l],160 to 580,84694,DB00514,Dextromethorphan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,27,85677,DB00514,Dextromethorphan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,54,85678,DB00514,Dextromethorphan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,44,85679,DB00514,Dextromethorphan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,160,85680,DB00514,Dextromethorphan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,74,85681,DB00514,Dextromethorphan
,21868471,clearance of midazolam (CYP3A),"Noncompartmental analysis showed that the clearance of midazolam (CYP3A) in CA hypothermia was reduced from sham normothermia rats (681.6 ± 190.0 versus 1268.8 ± 348.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],681.6,85784,DB00514,Dextromethorphan
,21868471,clearance of midazolam (CYP3A),"Noncompartmental analysis showed that the clearance of midazolam (CYP3A) in CA hypothermia was reduced from sham normothermia rats (681.6 ± 190.0 versus 1268.8 ± 348.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],1268.8,85785,DB00514,Dextromethorphan
,21868471,clearance,"The clearance of chlorzoxazone (CYP2E) in CA hypothermia was also reduced from sham normothermia rats (229.6 ± 75.6 versus 561.89 ± 215.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],229.6,85786,DB00514,Dextromethorphan
,21868471,clearance,"The clearance of chlorzoxazone (CYP2E) in CA hypothermia was also reduced from sham normothermia rats (229.6 ± 75.6 versus 561.89 ± 215.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],561.89,85787,DB00514,Dextromethorphan
,15500572,half-life,"Mean +/- SD values for half-life, apparent volume of distribution, and clearance after i.v. administration were 2.0 +/-0.6 h, 5.1 +/- 2.6 L/kg, and 33.8 +/- 16.5 mL/min/kg.",Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500572/),h,2.0,88082,DB00514,Dextromethorphan
,15500572,apparent volume of distribution,"Mean +/- SD values for half-life, apparent volume of distribution, and clearance after i.v. administration were 2.0 +/-0.6 h, 5.1 +/- 2.6 L/kg, and 33.8 +/- 16.5 mL/min/kg.",Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500572/),[l] / [kg],5.1,88083,DB00514,Dextromethorphan
,15500572,clearance,"Mean +/- SD values for half-life, apparent volume of distribution, and clearance after i.v. administration were 2.0 +/-0.6 h, 5.1 +/- 2.6 L/kg, and 33.8 +/- 16.5 mL/min/kg.",Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500572/),[ml] / [kg·min],33.8,88084,DB00514,Dextromethorphan
,15500572,Oral bioavailability,Oral bioavailability was 11% as calculated from naive pooled data.,Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500572/),%,11,88085,DB00514,Dextromethorphan
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.58,98193,DB00514,Dextromethorphan
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,2.1,98194,DB00514,Dextromethorphan
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.4,98195,DB00514,Dextromethorphan
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.1,98196,DB00514,Dextromethorphan
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.4,98197,DB00514,Dextromethorphan
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.5,98198,DB00514,Dextromethorphan
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.7,98199,DB00514,Dextromethorphan
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.3,98200,DB00514,Dextromethorphan
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,3.1,98201,DB00514,Dextromethorphan
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.8,98202,DB00514,Dextromethorphan
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.2,98203,DB00514,Dextromethorphan
,30681285,area under plasma concentration-time curve (AUC) ratio,"However, the geometric mean area under plasma concentration-time curve (AUC) ratio for dextromethorphan between treatment and control was 0.822, indicating a weak induction of dextromethorphan clearance following 13cisRA treatment.",Does In Vitro Cytochrome P450 Downregulation Translate to In Vivo Drug-Drug Interactions? Preclinical and Clinical Studies With 13-cis-Retinoic Acid. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30681285/),,0.822,98574,DB00514,Dextromethorphan
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.13,105121,DB00514,Dextromethorphan
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.27,105122,DB00514,Dextromethorphan
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0,105123,DB00514,Dextromethorphan
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.24,105124,DB00514,Dextromethorphan
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.34,105125,DB00514,Dextromethorphan
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.33,105126,DB00514,Dextromethorphan
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.58,105127,DB00514,Dextromethorphan
more,21050887,Drug release,Drug release at 12 h was more than 85%.,Floating matrix dosage form for dextromethorphan hydrobromide based on gas forming technique: in vitro and in vivo evaluation in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21050887/),%,85,106380,DB00514,Dextromethorphan
,20881950,clearance,"The clearance attributable to an individual CYP2D6*1 copy was 2.5-fold higher as compared with CYP2D6*2 (5,010 vs. 2,020 l/h), whereas the metabolic activity of CYP2D6*41 was very low (85 l/h).","Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881950/),[l] / [h],"5,010",106951,DB00514,Dextromethorphan
,20881950,clearance,"The clearance attributable to an individual CYP2D6*1 copy was 2.5-fold higher as compared with CYP2D6*2 (5,010 vs. 2,020 l/h), whereas the metabolic activity of CYP2D6*41 was very low (85 l/h).","Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881950/),[l] / [h],"2,020",106952,DB00514,Dextromethorphan
,8646830,partial metabolic clearance,Chronic renal failure was associated with a decrease in sparteine partial metabolic clearance to dehydrosparteine (median of 322 ml/min and range of 62 to 670 ml/min in patients with renal failure versus median of 635 ml/min and range of 77 to 1276 ml/min in normal subjects; p < 0.02).,Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646830/),[ml] / [min],322,109535,DB00514,Dextromethorphan
,8646830,partial metabolic clearance,Chronic renal failure was associated with a decrease in sparteine partial metabolic clearance to dehydrosparteine (median of 322 ml/min and range of 62 to 670 ml/min in patients with renal failure versus median of 635 ml/min and range of 77 to 1276 ml/min in normal subjects; p < 0.02).,Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646830/),[ml] / [min],635,109536,DB00514,Dextromethorphan
,8646830,fractional urinary excretion,"Although fractional urinary excretion of dextrorphan decreased in patients with renal failure (median, 24.4%; range, 9.7% to 55.9%) compared with control (median, 47.5%; range, 24.1% to 72.1%) (p = 0.02), it also showed that all subjects were extensive metabolizers of dextromethorphan.",Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646830/),%,24.4,109537,DB00514,Dextromethorphan
,8646830,fractional urinary excretion,"Although fractional urinary excretion of dextrorphan decreased in patients with renal failure (median, 24.4%; range, 9.7% to 55.9%) compared with control (median, 47.5%; range, 24.1% to 72.1%) (p = 0.02), it also showed that all subjects were extensive metabolizers of dextromethorphan.",Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646830/),%,47.5,109538,DB00514,Dextromethorphan
,11343579,S-Cit/R-Cit ratio,"Plasma concentrations of S-Cit and R-Cit significantly increased from day 0 (means+/-S.D.: 28+/-9 and 47+/-11 &mgr;g/l, respectively) to day 49 (58+/-12 and 72+/-21 &mgr;g/l, respectively) (p & 0.01 for each comparison), and the S-Cit/R-Cit ratio increased from 0.61+/-0.16 to 0.82+/-0.12 (p & 0.01).",Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11343579/),,0.61,116091,DB00514,Dextromethorphan
,11343579,S-Cit/R-Cit ratio,"Plasma concentrations of S-Cit and R-Cit significantly increased from day 0 (means+/-S.D.: 28+/-9 and 47+/-11 &mgr;g/l, respectively) to day 49 (58+/-12 and 72+/-21 &mgr;g/l, respectively) (p & 0.01 for each comparison), and the S-Cit/R-Cit ratio increased from 0.61+/-0.16 to 0.82+/-0.12 (p & 0.01).",Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11343579/),,0.82,116092,DB00514,Dextromethorphan
,10613613,urinary metabolic ratio,Dextromethorphan urinary metabolic ratio increased from -2.52 +/- 0.67 to -2.03 +/- 0.58 (P < .001) in the presence of chloroguanide.,Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613613/),,2.52,117511,DB00514,Dextromethorphan
,10613613,urinary metabolic ratio,Dextromethorphan urinary metabolic ratio increased from -2.52 +/- 0.67 to -2.03 +/- 0.58 (P < .001) in the presence of chloroguanide.,Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613613/),,2.03,117512,DB00514,Dextromethorphan
,15333515,systemic clearance,The systemic clearance of propranolol (approximately 1.53 l/h/kg) suggested that the hepatic blood flow in CHPs is comparable to that in humans.,The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333515/),[l] / [h·kg],1.53,119920,DB00514,Dextromethorphan
,27580115,Metabolic ratios,"Metabolic ratios for dextromethorphan ranged from 0.03 to 0.46 (mean, 0.12).",Dextromethorphan and debrisoquine metabolism and polymorphism of the gene for cytochrome P450 isozyme 2D50 in Thoroughbreds. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27580115/),,0.12,125070,DB00514,Dextromethorphan
,8436164,plasma ratio,"There was only a minor pharmacokinetic interaction between amitriptyline (AMT) and toloxatone, with a small increase in the AMT/NT (nortriptyline) plasma ratio: 0.68 before and 0.78 after toloxatone.",Minor and clinically non-significant interaction between toloxatone and amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436164/),,0.68,125236,DB00514,Dextromethorphan
,8436164,plasma ratio,"There was only a minor pharmacokinetic interaction between amitriptyline (AMT) and toloxatone, with a small increase in the AMT/NT (nortriptyline) plasma ratio: 0.68 before and 0.78 after toloxatone.",Minor and clinically non-significant interaction between toloxatone and amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436164/),,0.78,125237,DB00514,Dextromethorphan
,20006596,K(i),SCH 486757 selectively binds human NOP receptor (K(i)=4.6+/-0.61nM) over classical opioid receptors.,Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006596/),nM,4.6,132212,DB00514,Dextromethorphan
>,10599932,metabolic ratio,"The CYP2D6 phenotype, determined when the patient received the antidepressant comedication, characterized a poor metabolizer status (dextromethorphan metabolic ratio >0.3), despite a heterozygous genotype containing a wild-type allele with extensive metabolic capacity and a mutant non-functional allele (CYP2D6*1A/CYP2D6*4A).",Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599932/),,0.3,133345,DB00514,Dextromethorphan
,31587004,oral bioavailability,"Subsequently, pharmacokinetic study showed that the oral bioavailability of WZ35 is 10.56%.",Cytochrome P450-Mediated Metabolic Characterization of a Mono-Carbonyl Curcumin Analog WZ35. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587004/),%,10.56,135697,DB00514,Dextromethorphan
,27580591,Cmax,"The Cmax , Tmax , and the t1/2 of dextromethorphan were 519.4 ng/mL, 0.55 h, and 12.4 h respectively.",Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27580591/),[ng] / [ml],519.4,140905,DB00514,Dextromethorphan
,27580591,Tmax,"The Cmax , Tmax , and the t1/2 of dextromethorphan were 519.4 ng/mL, 0.55 h, and 12.4 h respectively.",Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27580591/),h,0.55,140906,DB00514,Dextromethorphan
,27580591,t1/2,"The Cmax , Tmax , and the t1/2 of dextromethorphan were 519.4 ng/mL, 0.55 h, and 12.4 h respectively.",Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27580591/),h,12.4,140907,DB00514,Dextromethorphan
,27580591,area under the curve,"The area under the curve of dextromethorphan, free dextrorphan, and conjugated dextrorphan were 563.8, 2.19, and 6,691 h*ng/mL respectively.",Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27580591/),[h·ng] / [ml],563.8,140908,DB00514,Dextromethorphan
,27580591,area under the curve,"The area under the curve of dextromethorphan, free dextrorphan, and conjugated dextrorphan were 563.8, 2.19, and 6,691 h*ng/mL respectively.",Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27580591/),[h·ng] / [ml],2.19,140909,DB00514,Dextromethorphan
,27580591,area under the curve,"The area under the curve of dextromethorphan, free dextrorphan, and conjugated dextrorphan were 563.8, 2.19, and 6,691 h*ng/mL respectively.",Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27580591/),[h·ng] / [ml],"6,691",140910,DB00514,Dextromethorphan
,22853867,relative AUC0-12 ratio,The relative AUC0-12 ratio of lansoprazole in EMs and PMs was 1:3.3 - 4.3.,Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22853867/),,1,142475,DB00514,Dextromethorphan
,22651995,flow-rate,"Chromatographic separation was performed by pumping the mobile phase (acetonitrile/water/formic acid (90/9/1, v/v/v) during 4.0min at a flow-rate of 1.5 mL min⁻¹ into a Phenomenex Gemini® C18, 5 μm analytical column (150 × 4.6 mm i.d.).","Simultaneous determination of dextromethorphan, dextrorphan and doxylamine in human plasma by HPLC coupled to electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22651995/),min⁻¹·ml,1.5,143636,DB00514,Dextromethorphan
,22651995,run-time,The run-time was for 4 min.,"Simultaneous determination of dextromethorphan, dextrorphan and doxylamine in human plasma by HPLC coupled to electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22651995/),min,4,143637,DB00514,Dextromethorphan
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],19.9,143867,DB00514,Dextromethorphan
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],6.2,143868,DB00514,Dextromethorphan
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],22.5,143869,DB00514,Dextromethorphan
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],21.0,143870,DB00514,Dextromethorphan
,15018793,recoveries,The recoveries were between 88.0 and 108.6%.,Simple chromatography method for simultaneous determination of dextromethorphan and its main metabolites in human plasma with fluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018793/),%,88.0 and 108.6,147331,DB00514,Dextromethorphan
,24710899,IC50,"In the in vitro cytochrome P450 inhibition study, the rate of disappearance of testosterone was significantly reduced in the presence of 10 µM PU, while that of other cytochrome P450 substrates was not significantly affected in both human and rat liver microsomes, suggesting that puerarin inhibits the in vitro hepatic CYP3A-mediated metabolism in the human and rat systems (IC50 = 15.5 ± 3.9 µM).",In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710899/),μM,15.5,150775,DB00514,Dextromethorphan
,11225566,AUC0-12,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],522,153234,DB00514,Dextromethorphan
,11225566,AUC0-12,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],927,153235,DB00514,Dextromethorphan
,11225566,AUC,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],244,153236,DB00514,Dextromethorphan
,11225566,AUC,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],330,153237,DB00514,Dextromethorphan
,11225566,apparent oral clearance,Mean apparent oral clearance for both enantiomers decreased significantly with fluoxetine administration (R(+): 10.3 +/- 7.2 vs.,"Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),,10.3,153238,DB00514,Dextromethorphan
,11225566,S(-),"4.5 +/- 2.2 mL/min/kg; S(-): 22.5 +/- 12.3 vs. 12.6 +/- 7.4 mL/min/kg; p = 0.004 and 0.03, respectively).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[ml] / [kg·min],22.5,153239,DB00514,Dextromethorphan
,11225566,S(-),"4.5 +/- 2.2 mL/min/kg; S(-): 22.5 +/- 12.3 vs. 12.6 +/- 7.4 mL/min/kg; p = 0.004 and 0.03, respectively).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[ml] / [kg·min],12.6,153240,DB00514,Dextromethorphan
,10336580,peak plasma concentrations,"For the EM subjects, S-PPF was less rapidly metabolized and had higher peak plasma concentrations than R-PPF (413+/-143 vs 291+/-109 ng ml-1, P<0.001).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[ng] / [ml],413,154915,DB00514,Dextromethorphan
,10336580,peak plasma concentrations,"For the EM subjects, S-PPF was less rapidly metabolized and had higher peak plasma concentrations than R-PPF (413+/-143 vs 291+/-109 ng ml-1, P<0.001).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[ng] / [ml],291,154916,DB00514,Dextromethorphan
,10336580,AUC,"The AUC was markedly higher for S-PPF than for R-PPF (2214+/-776 vs 1639+/-630 microg h l-1, P<0.001), whereas the clearance of S-PPF was significantly lower than that of R-PPF (96.0+/-39.0 vs 138+/-78 l h-1, P<0.01).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[h·μg] / [l],2214,154917,DB00514,Dextromethorphan
,10336580,AUC,"The AUC was markedly higher for S-PPF than for R-PPF (2214+/-776 vs 1639+/-630 microg h l-1, P<0.001), whereas the clearance of S-PPF was significantly lower than that of R-PPF (96.0+/-39.0 vs 138+/-78 l h-1, P<0.01).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[h·μg] / [l],1639,154918,DB00514,Dextromethorphan
,10336580,clearance,"The AUC was markedly higher for S-PPF than for R-PPF (2214+/-776 vs 1639+/-630 microg h l-1, P<0.001), whereas the clearance of S-PPF was significantly lower than that of R-PPF (96.0+/-39.0 vs 138+/-78 l h-1, P<0.01).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[l] / [h],96.0,154919,DB00514,Dextromethorphan
,10336580,clearance,"The AUC was markedly higher for S-PPF than for R-PPF (2214+/-776 vs 1639+/-630 microg h l-1, P<0.001), whereas the clearance of S-PPF was significantly lower than that of R-PPF (96.0+/-39.0 vs 138+/-78 l h-1, P<0.01).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[l] / [h],138,154920,DB00514,Dextromethorphan
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],5036,156158,DB00514,Dextromethorphan
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],2854,156159,DB00514,Dextromethorphan
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],3255,156160,DB00514,Dextromethorphan
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],2125,156161,DB00514,Dextromethorphan
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],1069,156162,DB00514,Dextromethorphan
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],841,156163,DB00514,Dextromethorphan
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],947,156164,DB00514,Dextromethorphan
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],771,156165,DB00514,Dextromethorphan
,16778713,bioavailability,"The bioavailability of SIM compared with NEO was 54% to 71%, in agreement with previous results.",Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778713/),%,54,158024,DB00514,Dextromethorphan
,16778713,bioavailability,"The bioavailability of SIM compared with NEO was 54% to 71%, in agreement with previous results.",Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778713/),%,71,158025,DB00514,Dextromethorphan
,11192474,half-life,"The plasma concentration-time profile following oral administration is best described by a 1-compartment model, and the mean half-life (approximately 12 hours) is consistent with the recommendation to administer the drug twice daily.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),h,12,158838,DB00514,Dextromethorphan
,11192474,absolute bioavailability,"The absolute bioavailability is 94.5%, and maximal concentrations are generally achieved within 2 to 4 hours.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),%,94.5,158839,DB00514,Dextromethorphan
,11476153,pulmonary retention,"The average pulmonary retention of styrene was 62 +/- 7% at both exposure concentrations, and the 24-h excretion of MA and PGA accounted for 58% of the dose at both concentrations.",Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11476153/),%,62,162727,DB00514,Dextromethorphan
,11476153,apparent blood clearance,"Although other explanations cannot be excluded, this lack of correlation might be due to the high apparent blood clearance (1.4 l/min) of styrene, indicating that styrene metabolism is liver-blood-flow-dependent.",Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11476153/),[l] / [min],1.4,162728,DB00514,Dextromethorphan
,12403641,Absolute bioavailability,Absolute bioavailability is about 10% under fasted conditions.,"Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),%,10,165022,DB00514,Dextromethorphan
,12403641,volume of distribution at steady-state,"Tegaserod is approximately 98% bound to plasma proteins, primarily to alpha(1)-acid glycoprotein, and has a volume of distribution at steady-state of 368 +/- 223L.","Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),l,368,165023,DB00514,Dextromethorphan
,12403641,plasma clearance,"The plasma clearance of tegaserod is 77 +/- 15 L/h, with an estimated terminal half-life of 11 +/- 5 hours following intravenous administration.","Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),[l] / [h],77,165024,DB00514,Dextromethorphan
,12403641,terminal half-life,"The plasma clearance of tegaserod is 77 +/- 15 L/h, with an estimated terminal half-life of 11 +/- 5 hours following intravenous administration.","Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),h,11,165025,DB00514,Dextromethorphan
,17431033,K(m),The K(m) value for the formation of M1 was 23.8 microM in human liver microsomes.,Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),μM,23.8,166307,DB00514,Dextromethorphan
,17431033,K(i),"The CYP2D6 inhibitor quinidine proved a potent competitive inhibitor of timolol metabolism, with an in vitro K(i) value of 0.08 microM.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),μM,0.08,166308,DB00514,Dextromethorphan
,17431033,half-life,"Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),h,3,166309,DB00514,Dextromethorphan
,17431033,half-life,"Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),h,2 to 5,166310,DB00514,Dextromethorphan
,14749695,systemic clearance,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],32,166423,DB00514,Dextromethorphan
,14749695,systemic clearance,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],43,166424,DB00514,Dextromethorphan
,14749695,area under the concentration-time curve,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),μg,127,166425,DB00514,Dextromethorphan
,14749695,oral clearance,"In contrast, the oral clearance of midazolam was not significantly altered (P =.655; 90% CI, 75%-124%), 137 +/- 19 L/h compared with 146 +/- 71 L/h.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],137,166426,DB00514,Dextromethorphan
,14749695,oral clearance,"In contrast, the oral clearance of midazolam was not significantly altered (P =.655; 90% CI, 75%-124%), 137 +/- 19 L/h compared with 146 +/- 71 L/h.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],146,166427,DB00514,Dextromethorphan
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),%,108,166428,DB00514,Dextromethorphan
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.23,166429,DB00514,Dextromethorphan
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.33,166430,DB00514,Dextromethorphan
,14749695,Hepatic availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.72,166431,DB00514,Dextromethorphan
,14749695,Hepatic availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.61,166432,DB00514,Dextromethorphan
,14749695,intestinal availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.33,166433,DB00514,Dextromethorphan
,14749695,intestinal availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.61,166434,DB00514,Dextromethorphan
,14749695,oral clearance,"Echinacea dosing significantly reduced the oral clearance of caffeine, from 6.6 +/- 3.8 L/h to 4.9 +/- 2.3 L/h (P =.049; 90% CI, 58%-96%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],6.6,166435,DB00514,Dextromethorphan
,14749695,oral clearance,"Echinacea dosing significantly reduced the oral clearance of caffeine, from 6.6 +/- 3.8 L/h to 4.9 +/- 2.3 L/h (P =.049; 90% CI, 58%-96%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],4.9,166436,DB00514,Dextromethorphan
,14749695,oral clearance,"The oral clearance of tolbutamide was reduced by 11%, from 0.81 +/- 0.18 L/h to 0.72 +/- 0.19 L/h, but this change was not considered to be clinically relevant because the 90% CIs were within the 80% to 125% range.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],0.81,166437,DB00514,Dextromethorphan
,14749695,oral clearance,"The oral clearance of tolbutamide was reduced by 11%, from 0.81 +/- 0.18 L/h to 0.72 +/- 0.19 L/h, but this change was not considered to be clinically relevant because the 90% CIs were within the 80% to 125% range.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],0.72,166438,DB00514,Dextromethorphan
,14749695,oral clearance,"The oral clearance of dextromethorphan in 11 CYP2D6 extensive metabolizers was not affected by echinacea dosing (1289 +/- 414 L/h compared with 1281 +/- 483 L/h; P =.732; 90% CI, 89%-108%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],1289,166439,DB00514,Dextromethorphan
,14749695,oral clearance,"The oral clearance of dextromethorphan in 11 CYP2D6 extensive metabolizers was not affected by echinacea dosing (1289 +/- 414 L/h compared with 1281 +/- 483 L/h; P =.732; 90% CI, 89%-108%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],1281,166440,DB00514,Dextromethorphan
,10579479,metabolic ratios,"Mean CYP2D6 dextromethorphan metabolic ratios before and after fluoxetine therapy were 0.028 +/- 0.031 and 0.080 +/- 0.058, respectively (P = .001), indicating that a strong inhibition of CYP2D6 by fluoxetine activity was observed in Chinese subjects.",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),,0.028,169584,DB00514,Dextromethorphan
,10579479,metabolic ratios,"Mean CYP2D6 dextromethorphan metabolic ratios before and after fluoxetine therapy were 0.028 +/- 0.031 and 0.080 +/- 0.058, respectively (P = .001), indicating that a strong inhibition of CYP2D6 by fluoxetine activity was observed in Chinese subjects.",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),,0.080,169585,DB00514,Dextromethorphan
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],75.01,169586,DB00514,Dextromethorphan
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],49.36,169587,DB00514,Dextromethorphan
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],107.62,169588,DB00514,Dextromethorphan
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],70.60,169589,DB00514,Dextromethorphan
,15328251,DMR,The DMR was 0.214 +/- 0.025 at baseline and 0.254 +/- 0.026 after valerian supplementation (p > 0.05).,Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),,0.214,172895,DB00514,Dextromethorphan
,15328251,DMR,The DMR was 0.214 +/- 0.025 at baseline and 0.254 +/- 0.026 after valerian supplementation (p > 0.05).,Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),,0.254,172896,DB00514,Dextromethorphan
,15328251,maximum concentration,"For alprazolam, the maximum concentration in plasma was significantly increased after treatment with valerian (25 +/- 7 ng/ml versus 31 +/- 8 ng/ml; p < 0.05).",Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),[ng] / [ml],25,172897,DB00514,Dextromethorphan
,15328251,maximum concentration,"For alprazolam, the maximum concentration in plasma was significantly increased after treatment with valerian (25 +/- 7 ng/ml versus 31 +/- 8 ng/ml; p < 0.05).",Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),[ng] / [ml],31,172898,DB00514,Dextromethorphan
,15328251,time to reach maximum concentration,"There were no significant differences in other pharmacokinetic parameters at baseline and after valerian exposure (all p values > or = 0.05; time to reach maximum concentration in plasma, 3.0 +/- 3.2 versus 3.1 +/- 2.1 h; area under the plasma concentration versus time curve, 471 +/- 183 versus 539 +/- 240 hx ng x ml(-1); half-life of elimination, 13.5 +/- 4.3 versus 12.2 +/- 5.6 h).",Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),h,3.0,172899,DB00514,Dextromethorphan
,15328251,time to reach maximum concentration,"There were no significant differences in other pharmacokinetic parameters at baseline and after valerian exposure (all p values > or = 0.05; time to reach maximum concentration in plasma, 3.0 +/- 3.2 versus 3.1 +/- 2.1 h; area under the plasma concentration versus time curve, 471 +/- 183 versus 539 +/- 240 hx ng x ml(-1); half-life of elimination, 13.5 +/- 4.3 versus 12.2 +/- 5.6 h).",Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),h,3.1,172900,DB00514,Dextromethorphan
,15328251,area under the plasma concentration versus time curve,"There were no significant differences in other pharmacokinetic parameters at baseline and after valerian exposure (all p values > or = 0.05; time to reach maximum concentration in plasma, 3.0 +/- 3.2 versus 3.1 +/- 2.1 h; area under the plasma concentration versus time curve, 471 +/- 183 versus 539 +/- 240 hx ng x ml(-1); half-life of elimination, 13.5 +/- 4.3 versus 12.2 +/- 5.6 h).",Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),[h·ng] / [ml],471,172901,DB00514,Dextromethorphan
,15328251,area under the plasma concentration versus time curve,"There were no significant differences in other pharmacokinetic parameters at baseline and after valerian exposure (all p values > or = 0.05; time to reach maximum concentration in plasma, 3.0 +/- 3.2 versus 3.1 +/- 2.1 h; area under the plasma concentration versus time curve, 471 +/- 183 versus 539 +/- 240 hx ng x ml(-1); half-life of elimination, 13.5 +/- 4.3 versus 12.2 +/- 5.6 h).",Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),[h·ng] / [ml],539,172902,DB00514,Dextromethorphan
,15328251,half-life of elimination,"There were no significant differences in other pharmacokinetic parameters at baseline and after valerian exposure (all p values > or = 0.05; time to reach maximum concentration in plasma, 3.0 +/- 3.2 versus 3.1 +/- 2.1 h; area under the plasma concentration versus time curve, 471 +/- 183 versus 539 +/- 240 hx ng x ml(-1); half-life of elimination, 13.5 +/- 4.3 versus 12.2 +/- 5.6 h).",Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),h,13.5,172903,DB00514,Dextromethorphan
,15328251,half-life of elimination,"There were no significant differences in other pharmacokinetic parameters at baseline and after valerian exposure (all p values > or = 0.05; time to reach maximum concentration in plasma, 3.0 +/- 3.2 versus 3.1 +/- 2.1 h; area under the plasma concentration versus time curve, 471 +/- 183 versus 539 +/- 240 hx ng x ml(-1); half-life of elimination, 13.5 +/- 4.3 versus 12.2 +/- 5.6 h).",Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328251/),h,12.2,172904,DB00514,Dextromethorphan
,15657780,detection limits,IMs could be identified using dextromethorphan plasma assays with detection limits of at least 1 ng/ml.,Dextromethorphan metabolic phenotyping in an Iranian population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657780/),[ng] / [ml],1,172944,DB00514,Dextromethorphan
,25417559,flow rate,"Chromatographic separation was performed by pumping the mobile phase containing acetonitrile, water and formic acid (89.2:11.7:0.1) for 2.0 min at a flow rate of 0.25 μL/min into a Hypersil-Gold C18 column, 20 × 2.0 mm (1.9 µm) from Thermoscientific, New York, USA.","Development and validation of a sensitive UHPLC-MS/MS method for the simultaneous analysis of tramadol, dextromethorphan chlorpheniramine and their major metabolites in human plasma in forensic context: application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25417559/),[μl] / [min],0.25,178279,DB00514,Dextromethorphan
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,7.1,179595,DB00514,Dextromethorphan
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,3.7,179596,DB00514,Dextromethorphan
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,2.2,179597,DB00514,Dextromethorphan
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,1.7,179598,DB00514,Dextromethorphan
,15319329,maximum concentration,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),[ng] / [ml],33,182925,DB00514,Dextromethorphan
,15319329,maximum concentration,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),[ng] / [ml],34,182926,DB00514,Dextromethorphan
,15319329,time to reach maximum concentration,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),h,1.4,182927,DB00514,Dextromethorphan
,15319329,area under the plasma concentration versus time curve,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),[h·ng] / [ml],480,182928,DB00514,Dextromethorphan
,15319329,area under the plasma concentration versus time curve,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),[h·ng] / [ml],510,182929,DB00514,Dextromethorphan
,15319329,half-life of elimination,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),h,12.3,182930,DB00514,Dextromethorphan
,15319329,half-life of elimination,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),h,13.1,182931,DB00514,Dextromethorphan
,15319329,DMR,The DMR was 0.053 +/- 0.045 at baseline and 0.041 +/- 0.032 after DGT supplementation (P > 0.05).,Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),,0.053,182932,DB00514,Dextromethorphan
,15319329,DMR,The DMR was 0.053 +/- 0.045 at baseline and 0.041 +/- 0.032 after DGT supplementation (P > 0.05).,Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),,0.041,182933,DB00514,Dextromethorphan
,21350850,area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[h·mg] / [l],38.1,186875,DB00514,Dextromethorphan
,21350850,maximum plasma concentration (C(max)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[mg] / [l],4.9,186876,DB00514,Dextromethorphan
,1611804,plasma concentrations,"The same dose of dextromethorphan in the presence of 75 mg quinidine every 12 hours resulted in dextromethorphan plasma concentrations of 241 +/- 94 ng/ml (range, 157 to 402 ng/ml; n = 5).",Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611804/),[ng] / [ml],241,192012,DB00514,Dextromethorphan
up to,22283559,AU,"In group 1 (n = 14), addition of DMQ to paroxetine resulted in a 30% increase in mean plasma exposure of paroxetine (AUC up to 24 hours).",Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283559/),h,24,196520,DB00514,Dextromethorphan
,7690693,area under the concentration-time curve from time zero to infinity ratio,The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),,3,196714,DB00514,Dextromethorphan
,7690693,area under the concentration-time curve from time zero to infinity ratio,The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),,6,196715,DB00514,Dextromethorphan
,7690693,area under the concentration-time curve from time zero to infinity ratio,The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),,0.2,196716,DB00514,Dextromethorphan
,7690693,half-life,Risperidone half-life was about 3 hours in extensive metabolizers and 22 hours in poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),h,3,196717,DB00514,Dextromethorphan
,7690693,half-life,Risperidone half-life was about 3 hours in extensive metabolizers and 22 hours in poor metabolizers.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),h,22,196718,DB00514,Dextromethorphan
,7690693,absolute oral bioavailability,Risperidone absolute oral bioavailability was 66%.,Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),%,66,196719,DB00514,Dextromethorphan
,7690693,terminal half-life,"The pharmacokinetics of the active moiety (risperidone plus 9-hydroxyrisperidone) varied little among subjects (mean terminal half-life, 20 +/- 2 1/2 hours; absolute oral and intramuscular bioavailability, 100%).",Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),h,20,196720,DB00514,Dextromethorphan
,7690693,absolute oral,"The pharmacokinetics of the active moiety (risperidone plus 9-hydroxyrisperidone) varied little among subjects (mean terminal half-life, 20 +/- 2 1/2 hours; absolute oral and intramuscular bioavailability, 100%).",Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),%,100,196721,DB00514,Dextromethorphan
,7690693,intramuscular bioavailability,"The pharmacokinetics of the active moiety (risperidone plus 9-hydroxyrisperidone) varied little among subjects (mean terminal half-life, 20 +/- 2 1/2 hours; absolute oral and intramuscular bioavailability, 100%).",Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690693/),%,100,196722,DB00514,Dextromethorphan
more,17452028,extraction efficiency,The extraction efficiency was more than 79.5% for each of the six analytes.,"Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452028/),%,79.5,196786,DB00514,Dextromethorphan
,12485956,terminal elimination half-lives,"The elimination of traxoprodil was more rapid in EMs than in PMs with terminal elimination half-lives of 2.8 and 26.9 h, respectively, for EMs and PMs.","Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485956/),h,2.8,196795,DB00514,Dextromethorphan
,12485956,terminal elimination half-lives,"The elimination of traxoprodil was more rapid in EMs than in PMs with terminal elimination half-lives of 2.8 and 26.9 h, respectively, for EMs and PMs.","Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485956/),h,26.9,196796,DB00514,Dextromethorphan
,15964599,area under curve,"On the other hand, verapamil treatments increased the area under curve of DM in the brain (from 1221 to 2393 ng h/g) and spinal cord (from 1753 to 3221 ng h/g) by approximately 2-fold.",Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15964599/),[h·ng] / [g],1221 to 2393,200289,DB00514,Dextromethorphan
,15964599,area under curve,"On the other hand, verapamil treatments increased the area under curve of DM in the brain (from 1221 to 2393 ng h/g) and spinal cord (from 1753 to 3221 ng h/g) by approximately 2-fold.",Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15964599/),[h·ng] / [g],1753 to 3221,200290,DB00514,Dextromethorphan
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],90.37,202305,DB00514,Dextromethorphan
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],33.32,202306,DB00514,Dextromethorphan
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],16.93,202307,DB00514,Dextromethorphan
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],7.96,202308,DB00514,Dextromethorphan
,7593709,t1/2,"Pretreatment of these subjects with 100 mg of quinidine, a selective inhibitor of CYP2D6, significantly suppressed the formation of dextrorphan and elevated the concentrations of dextromethorphan (t1/2, 16.4 hours).",Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593709/),h,16.4,204576,DB00514,Dextromethorphan
,7593709,t1/2,"In poor metabolizers (N = 4) given the same dose, dextromethorphan was the major component in the plasma with a t1/2 of 29.5 hours.",Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593709/),h,29.5,204577,DB00514,Dextromethorphan
,12848776,intrinsic clearance,"The intrinsic clearance of DEX estimated from the model ranged from 59 to 1536 l x h(-1), which overlapped with that extrapolated from in vitro data (12-261 l x h(-1)) and showed similar variation (26- vs. 21-fold, respectively).",Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),[l] / [h],59 to 1536,209628,DB00514,Dextromethorphan
,12848776,intrinsic clearance,"The intrinsic clearance of DEX estimated from the model ranged from 59 to 1536 l x h(-1), which overlapped with that extrapolated from in vitro data (12-261 l x h(-1)) and showed similar variation (26- vs. 21-fold, respectively).",Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),[l] / [h],12-261,209629,DB00514,Dextromethorphan
,12848776,inhibitory effect,The inhibitory effect of quinidine ([I]/Ki) was 19 (95% confidence interval of mean: 18-20) with an estimated average Ki of 0.017 microM.,Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),,19,209630,DB00514,Dextromethorphan
,12848776,[I]/Ki,The inhibitory effect of quinidine ([I]/Ki) was 19 (95% confidence interval of mean: 18-20) with an estimated average Ki of 0.017 microM.,Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),,19,209631,DB00514,Dextromethorphan
,12848776,Ki,The inhibitory effect of quinidine ([I]/Ki) was 19 (95% confidence interval of mean: 18-20) with an estimated average Ki of 0.017 microM.,Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),μM,0.017,209632,DB00514,Dextromethorphan
,12848776,ke0,A sustained antitussive effect was related to slow removal of DEX/DOR from the effect site (ke0 = 0.07 h(-1)).,Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),1/[h],0.07,209633,DB00514,Dextromethorphan
,12705966,Limits of quantitation,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],10,214967,DB00514,Dextromethorphan
,12705966,Limits of quantitation,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],0.25,214968,DB00514,Dextromethorphan
,12705966,Limits of quantitation,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],0.19,214969,DB00514,Dextromethorphan
,12705966,Limits of quantitation,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],0.27,214970,DB00514,Dextromethorphan
,12705966,Limits of quantitation,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],0.22,214971,DB00514,Dextromethorphan
,12705966,S/N,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],10,214972,DB00514,Dextromethorphan
,12705966,S/N,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],0.25,214973,DB00514,Dextromethorphan
,12705966,S/N,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],0.19,214974,DB00514,Dextromethorphan
,12705966,S/N,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],0.27,214975,DB00514,Dextromethorphan
,12705966,S/N,"Limits of quantitation (S/N=10) in 100 microL of serum were 0.25, 0.19, 0.27, and 0.22 nmol/mL for 3-hydroxymorphinan, dextrorphan, 3-methoxymorphinan, and dextromethorphan, respectively.",Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705966/),[nM] / [ml],0.22,214976,DB00514,Dextromethorphan
,8841152,half-life,"The median dextromethorphan half-life was 19.1 hours in poor metabolizers, 5.6 hours in extensive metabolizers given quinidine, and 2.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,19.1,219662,DB00514,Dextromethorphan
,8841152,half-life,"The median dextromethorphan half-life was 19.1 hours in poor metabolizers, 5.6 hours in extensive metabolizers given quinidine, and 2.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,5.6,219663,DB00514,Dextromethorphan
,8841152,half-life,"The median dextromethorphan half-life was 19.1 hours in poor metabolizers, 5.6 hours in extensive metabolizers given quinidine, and 2.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,2.4,219664,DB00514,Dextromethorphan
,8841152,half-life,"The median half-life was 10.1 hours in poor metabolizers, 6.6 hours in extensive metabolizers given quinidine, and 1.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,10.1,219665,DB00514,Dextromethorphan
,8841152,half-life,"The median half-life was 10.1 hours in poor metabolizers, 6.6 hours in extensive metabolizers given quinidine, and 1.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,6.6,219666,DB00514,Dextromethorphan
,8841152,half-life,"The median half-life was 10.1 hours in poor metabolizers, 6.6 hours in extensive metabolizers given quinidine, and 1.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,1.4,219667,DB00514,Dextromethorphan
,8841152,apparent partial clearance,"The apparent partial clearance of dextromethorphan to dextrorphan was 1.2 L/hr in poor metabolizers, 78.5 L/hr in extensive metabolizers given quinidine, and 970 L/hr in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),[l] / [h],1.2,219668,DB00514,Dextromethorphan
,8841152,apparent partial clearance,"The apparent partial clearance of dextromethorphan to dextrorphan was 1.2 L/hr in poor metabolizers, 78.5 L/hr in extensive metabolizers given quinidine, and 970 L/hr in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),[l] / [h],78.5,219669,DB00514,Dextromethorphan
,8841152,apparent partial clearance,"The apparent partial clearance of dextromethorphan to dextrorphan was 1.2 L/hr in poor metabolizers, 78.5 L/hr in extensive metabolizers given quinidine, and 970 L/hr in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),[l] / [h],970,219670,DB00514,Dextromethorphan
,15096109,ED(50),Quinidine coadministration resulted in a more than twofold increase in the area under the curve of DM with an ED(50) of approximately 2 mg/kg whereas those of total DX were only increased by 21%.,Influence of concomitant quinidine administration on dextromethorphan disposition in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096109/),[mg] / [kg],2,222163,DB00514,Dextromethorphan
less,32738202,Ki,The Ki values in this study were less than 8.32 μM.,Evaluation of acacetin inhibition potential against cytochrome P450 in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32738202/),μM,8.32,223492,DB00514,Dextromethorphan
,2049245,time to achieve maximum plasma codeine concentrations,"2. After the single dose, the time to achieve maximum plasma codeine concentrations was 0.97 +/- 0.31 h (mean +/- s.d.) and for codeine-6-glucuronide it was 1.28 +/- 0.49 h.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,0.97,223560,DB00514,Dextromethorphan
,2049245,time to achieve maximum plasma codeine concentrations,"2. After the single dose, the time to achieve maximum plasma codeine concentrations was 0.97 +/- 0.31 h (mean +/- s.d.) and for codeine-6-glucuronide it was 1.28 +/- 0.49 h.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,1.28,223561,DB00514,Dextromethorphan
,2049245,elimination half-life,The elimination half-life of codeine was 3.2 +/- 0.3 h and that of codeine-6-glucuronide was 3.2 +/- 0.9 h.,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,3.2,223562,DB00514,Dextromethorphan
,2049245,elimination half-life,The elimination half-life of codeine was 3.2 +/- 0.3 h and that of codeine-6-glucuronide was 3.2 +/- 0.9 h.,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,3.2,223563,DB00514,Dextromethorphan
,2049245,renal clearance,3. The renal clearance of codeine was 183 +/- 59 ml min-1 and was inversely correlated with urine pH (r = 0.81).,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],183,223564,DB00514,Dextromethorphan
,2049245,renal clearance,"The renal clearance of codeine-6-glucuronide was 55 +/- 21 ml min-1, and was not correlated with urine pH.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],55,223565,DB00514,Dextromethorphan
less,2049245,binding,Its binding to human plasma was less than 10%.,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),%,10,223566,DB00514,Dextromethorphan
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],137,223567,DB00514,Dextromethorphan
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],8,223568,DB00514,Dextromethorphan
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],103,223569,DB00514,Dextromethorphan
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],90,223570,DB00514,Dextromethorphan
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],914,223571,DB00514,Dextromethorphan
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],971,223572,DB00514,Dextromethorphan
,2049245,intrinsic clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],1568,223573,DB00514,Dextromethorphan
,2049245,intrinsic clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],1450,223574,DB00514,Dextromethorphan
,12891227,maximum concentration,"For alprazolam, there were no significant differences in pharmacokinetic parameters at baseline and after garlic extract treatment (all P values > or =.05; maximum concentration in plasma, 27.3 +/- 2.6 ng/mL versus 27.3 +/- 4.8 ng/mL; time to reach maximum concentration in plasma, 1.9 +/- 1.4 h versus 2.4 +/- 1.8 h; area under the time-versus-concentration curve, 537 +/- 94 h.",Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891227/),[ng] / [ml],27.3,226746,DB00514,Dextromethorphan
,12891227,maximum concentration,"For alprazolam, there were no significant differences in pharmacokinetic parameters at baseline and after garlic extract treatment (all P values > or =.05; maximum concentration in plasma, 27.3 +/- 2.6 ng/mL versus 27.3 +/- 4.8 ng/mL; time to reach maximum concentration in plasma, 1.9 +/- 1.4 h versus 2.4 +/- 1.8 h; area under the time-versus-concentration curve, 537 +/- 94 h.",Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891227/),[ng] / [ml],27.3,226747,DB00514,Dextromethorphan
,12891227,time to reach maximum concentration,"For alprazolam, there were no significant differences in pharmacokinetic parameters at baseline and after garlic extract treatment (all P values > or =.05; maximum concentration in plasma, 27.3 +/- 2.6 ng/mL versus 27.3 +/- 4.8 ng/mL; time to reach maximum concentration in plasma, 1.9 +/- 1.4 h versus 2.4 +/- 1.8 h; area under the time-versus-concentration curve, 537 +/- 94 h.",Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891227/),h,1.9,226748,DB00514,Dextromethorphan
,12891227,time to reach maximum concentration,"For alprazolam, there were no significant differences in pharmacokinetic parameters at baseline and after garlic extract treatment (all P values > or =.05; maximum concentration in plasma, 27.3 +/- 2.6 ng/mL versus 27.3 +/- 4.8 ng/mL; time to reach maximum concentration in plasma, 1.9 +/- 1.4 h versus 2.4 +/- 1.8 h; area under the time-versus-concentration curve, 537 +/- 94 h.",Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891227/),h,2.4,226749,DB00514,Dextromethorphan
,12891227,area under the time-versus-concentration curve,"For alprazolam, there were no significant differences in pharmacokinetic parameters at baseline and after garlic extract treatment (all P values > or =.05; maximum concentration in plasma, 27.3 +/- 2.6 ng/mL versus 27.3 +/- 4.8 ng/mL; time to reach maximum concentration in plasma, 1.9 +/- 1.4 h versus 2.4 +/- 1.8 h; area under the time-versus-concentration curve, 537 +/- 94 h.",Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891227/),h,537,226750,DB00514,Dextromethorphan
,12891227,half-life of elimination,"ng. mL(-1) versus 548 +/- 159 h. ng. mL(-1); half-life of elimination, 13.7 +/- 4.4 h versus 14.5 +/- 4.3 h).",Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891227/),h,13.7,226751,DB00514,Dextromethorphan
,12891227,half-life of elimination,"ng. mL(-1) versus 548 +/- 159 h. ng. mL(-1); half-life of elimination, 13.7 +/- 4.4 h versus 14.5 +/- 4.3 h).",Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891227/),h,14.5,226752,DB00514,Dextromethorphan
,18794647,metabolic ratio,"The metabolic ratio increased almost 100-fold from 0.0061 +/- 0.0056 to 0.4322 +/- 0.2848 after MDMA administration, with 67% of the subjects having a value greater than the antimode of 0.3 for assigning the poor metabolizer phenotype.","The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794647/),,0.00,233432,DB00514,Dextromethorphan
,18794647,metabolic ratio,"The metabolic ratio increased almost 100-fold from 0.0061 +/- 0.0056 to 0.4322 +/- 0.2848 after MDMA administration, with 67% of the subjects having a value greater than the antimode of 0.3 for assigning the poor metabolizer phenotype.","The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794647/),,0.,233433,DB00514,Dextromethorphan
,18794647,recovery half-life,CYP2D6 activity recovered after 10 days with a recovery half-life of 46.6 hours.,"The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794647/),h,46.6,233434,DB00514,Dextromethorphan
,22822534,flow rate,The flow rate was 0.4 mL/min.,Simultaneous determination of dextromethorphan and dextrophan in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22822534/),[ml] / [min],0.4,234885,DB00514,Dextromethorphan
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,47.30,238596,DB00514,Dextromethorphan
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,33.23,238597,DB00514,Dextromethorphan
,7562518,brain/plasma concentration ratio,"Plasma dextromethorphan was correlated with brain dextromethorphan (r = 0.84, P < .001), and the brain/plasma concentration ratio was about 6.5.",Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562518/),,6.5,244810,DB00514,Dextromethorphan
,7562518,Tmax,"Tmax of brain dextrorphan was earlier, and Cmax was higher after i.p. injection of dextromethorphan than s.c. administration (60 min vs. 120 min and 1.0 nmol/g vs. 0.2 nmol/g).",Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562518/),min,60,244811,DB00514,Dextromethorphan
,7562518,Tmax,"Tmax of brain dextrorphan was earlier, and Cmax was higher after i.p. injection of dextromethorphan than s.c. administration (60 min vs. 120 min and 1.0 nmol/g vs. 0.2 nmol/g).",Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562518/),min,120,244812,DB00514,Dextromethorphan
,7562518,Cmax,"Tmax of brain dextrorphan was earlier, and Cmax was higher after i.p. injection of dextromethorphan than s.c. administration (60 min vs. 120 min and 1.0 nmol/g vs. 0.2 nmol/g).",Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562518/),[nM] / [g],1.0,244813,DB00514,Dextromethorphan
,7562518,Cmax,"Tmax of brain dextrorphan was earlier, and Cmax was higher after i.p. injection of dextromethorphan than s.c. administration (60 min vs. 120 min and 1.0 nmol/g vs. 0.2 nmol/g).",Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562518/),[nM] / [g],0.2,244814,DB00514,Dextromethorphan
,9571226,cumulative excretion,"One week after administration of the dose, cumulative excretion amounted to 67.8 +/- 2.5% in the urine and 22.0 +/- 5.6% in the feces.","Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571226/),%,67.8,255209,DB00514,Dextromethorphan
,9571226,cumulative excretion,"One week after administration of the dose, cumulative excretion amounted to 67.8 +/- 2.5% in the urine and 22.0 +/- 5.6% in the feces.","Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571226/),%,22.0,255210,DB00514,Dextromethorphan
,9571226,maximum plasma concentration,"Mean maximum plasma concentration values for unchanged CP-93,393 were 10.92 and 1.02 ng/ml for poor metabolizers (PMs) and extensive metabolizers (EMs) of dextromethorphan, respectively.","Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571226/),[ng] / [ml],10.92,255211,DB00514,Dextromethorphan
,9571226,maximum plasma concentration,"Mean maximum plasma concentration values for unchanged CP-93,393 were 10.92 and 1.02 ng/ml for poor metabolizers (PMs) and extensive metabolizers (EMs) of dextromethorphan, respectively.","Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571226/),[ng] / [ml],1.02,255212,DB00514,Dextromethorphan
,17652181,K(i),"In vitro study has demonstrated that cinacalcet is a potent inhibitor of cytochrome P450 (CYP) 2D6 with a K(i) value of 0.087 micromol/L, which is comparable to the well-known potent CYP2D6 inhibitor, quinidine (0.064 micromol/L).","Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652181/),[μM] / [l],0.087,255651,DB00514,Dextromethorphan
,17652181,K(i),"In vitro study has demonstrated that cinacalcet is a potent inhibitor of cytochrome P450 (CYP) 2D6 with a K(i) value of 0.087 micromol/L, which is comparable to the well-known potent CYP2D6 inhibitor, quinidine (0.064 micromol/L).","Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652181/),[μM] / [l],0.064,255652,DB00514,Dextromethorphan
,9547706,flow rate,"At a flow rate of 1.5 ml min-1, a complete analysis was completed in less than 6 min.",Simplified reversed-phase HPLC method with spectrophotometric detection for the assay of verapamil in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547706/),[ml] / [min],1.5,256381,DB00514,Dextromethorphan
,9547706,Recoveries,Recoveries for the same drug concentrations from spiked rat plasma ranged from 85.6-93.0% (n = 8).,Simplified reversed-phase HPLC method with spectrophotometric detection for the assay of verapamil in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547706/),%,85.6-93.0,256382,DB00514,Dextromethorphan
,9547706,limit of detectability,The limit of detectability was about 0.1 microgram ml-1.,Simplified reversed-phase HPLC method with spectrophotometric detection for the assay of verapamil in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547706/),[μg] / [ml],0.1,256383,DB00514,Dextromethorphan
,10848718,area under the plasma concentration-time curve,"Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 +/- 4.6%) and maximal plasma concentrations (72 +/- 6.9%) of metoprolol.",Influence of hydroxychloroquine on the bioavailability of oral metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10848718/),%,65,256387,DB00514,Dextromethorphan
,10848718,maximal plasma concentrations,"Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 +/- 4.6%) and maximal plasma concentrations (72 +/- 6.9%) of metoprolol.",Influence of hydroxychloroquine on the bioavailability of oral metoprolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10848718/),%,72,256388,DB00514,Dextromethorphan
,31268632,Ratio of,We obtained good predictions for the dextromethorphan-duloxetine interaction (Ratio of predicted over observed area under the curve (AUC) ratio (Rpred/obs ) 1.38-1.43).,Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31268632/),,1.38-1.43,257178,DB00514,Dextromethorphan
,31268632,area under the curve (AU,We obtained good predictions for the dextromethorphan-duloxetine interaction (Ratio of predicted over observed area under the curve (AUC) ratio (Rpred/obs ) 1.38-1.43).,Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31268632/),,1.38-1.43,257179,DB00514,Dextromethorphan
,31268632,Rpred/obs,"Despite an approximately twofold underprediction of the dextromethorphan-paroxetine interaction, an Rpred/obs of 0.71 was obtained for the effect of genotype on the area under the curve ratio.",Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31268632/),,0.71,257180,DB00514,Dextromethorphan
,16984212,oral bioavailability,"In poor metabolisers (n = 6), oral bioavailability was approximately 80% and was consistent with a liver extraction ratio of approximately 20% (plasma clearance of approximately 4 mL/min/kg) indicating near complete absorption.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),%,80,259688,DB00514,Dextromethorphan
,16984212,liver extraction ratio,"In poor metabolisers (n = 6), oral bioavailability was approximately 80% and was consistent with a liver extraction ratio of approximately 20% (plasma clearance of approximately 4 mL/min/kg) indicating near complete absorption.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),%,20,259689,DB00514,Dextromethorphan
,16984212,plasma clearance,"In poor metabolisers (n = 6), oral bioavailability was approximately 80% and was consistent with a liver extraction ratio of approximately 20% (plasma clearance of approximately 4 mL/min/kg) indicating near complete absorption.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),[ml] / [kg·min],4,259690,DB00514,Dextromethorphan
,16984212,volume of distribution at steady state (V(ss)),"Following intravenous administration, the mean volume of distribution at steady state (V(ss)) was moderate (approximately 6.5 L/kg) and the mean elimination half-life (t((1/2))) was approximately 20 hours.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),[l] / [kg],6.5,259691,DB00514,Dextromethorphan
,16984212,elimination half-life (t((1/2))),"Following intravenous administration, the mean volume of distribution at steady state (V(ss)) was moderate (approximately 6.5 L/kg) and the mean elimination half-life (t((1/2))) was approximately 20 hours.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),h,20,259692,DB00514,Dextromethorphan
,16984212,absolute oral bioavailability,"At the 100mg dose, the absolute oral bioavailability was approximately 39.5%.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),%,39.5,259693,DB00514,Dextromethorphan
,16984212,oral bioavailability,"Overall, the oral bioavailability ranged from 22.8% to 62.1% and its estimation was confounded by large differences in plasma concentrations at oral doses without equivalent intravenous doses.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),%,22.8,259694,DB00514,Dextromethorphan
,16984212,oral bioavailability,"Overall, the oral bioavailability ranged from 22.8% to 62.1% and its estimation was confounded by large differences in plasma concentrations at oral doses without equivalent intravenous doses.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),%,62.1,259695,DB00514,Dextromethorphan
,16984212,plasma clearance,"Following intravenous administration, plasma clearance was high (approximately 27 mL/min/kg), the V(ss) was moderate (approximately 4 L/Kg) and the t((1/2)) was approximately 2-4 hours.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),[ml] / [kg·min],27,259696,DB00514,Dextromethorphan
,16984212,V(ss),"Following intravenous administration, plasma clearance was high (approximately 27 mL/min/kg), the V(ss) was moderate (approximately 4 L/Kg) and the t((1/2)) was approximately 2-4 hours.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),[l] / [kg],4,259697,DB00514,Dextromethorphan
,16984212,t((1/2)),"Following intravenous administration, plasma clearance was high (approximately 27 mL/min/kg), the V(ss) was moderate (approximately 4 L/Kg) and the t((1/2)) was approximately 2-4 hours.",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),h,2-4,259698,DB00514,Dextromethorphan
,16984212,t((1/2)),"However, t((1/2)) was approximately the same at all doses (approximately 4 hours).",Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16984212/),h,4,259699,DB00514,Dextromethorphan
,21870106,T(max),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.03,259984,DB00514,Dextromethorphan
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.66,259985,DB00514,Dextromethorphan
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.66,259986,DB00514,Dextromethorphan
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.99,259987,DB00514,Dextromethorphan
,8006199,oral clearance,"The mean (SD) oral clearance and half-life of clozapine were 55.4 (29.7) L/hr and 13.7 (9.9) hours, respectively.",Disposition of clozapine and desmethylclozapine in schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8006199/),[l] / [h],55.4,261122,DB00514,Dextromethorphan
,8006199,half-life,"The mean (SD) oral clearance and half-life of clozapine were 55.4 (29.7) L/hr and 13.7 (9.9) hours, respectively.",Disposition of clozapine and desmethylclozapine in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8006199/),h,13.7,261123,DB00514,Dextromethorphan
,8006199,AUC,"The mean (SD) AUC for clozapine and desmethylclozapine was 2389.9 (1406) and 751.1 (622.9) ng.hr/mL, respectively.",Disposition of clozapine and desmethylclozapine in schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8006199/),[h·ng] / [ml],2389.9,261124,DB00514,Dextromethorphan
,8006199,AUC,"The mean (SD) AUC for clozapine and desmethylclozapine was 2389.9 (1406) and 751.1 (622.9) ng.hr/mL, respectively.",Disposition of clozapine and desmethylclozapine in schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8006199/),[h·ng] / [ml],751.1,261125,DB00514,Dextromethorphan
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5370,262206,DB00514,Dextromethorphan
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5246,262207,DB00514,Dextromethorphan
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.43,262208,DB00514,Dextromethorphan
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.87,262209,DB00514,Dextromethorphan
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.23,262210,DB00514,Dextromethorphan
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.11,262211,DB00514,Dextromethorphan
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],677.9,262212,DB00514,Dextromethorphan
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],466.9,262213,DB00514,Dextromethorphan
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,207",262214,DB00514,Dextromethorphan
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,688",262215,DB00514,Dextromethorphan
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],34.85,262216,DB00514,Dextromethorphan
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],37.27,262217,DB00514,Dextromethorphan
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],92.07,262218,DB00514,Dextromethorphan
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],93.04,262219,DB00514,Dextromethorphan
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1428,262220,DB00514,Dextromethorphan
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1499,262221,DB00514,Dextromethorphan
,21269969,AUC,Pharmacokinetic analysis of the new dextromethorphan chewing gum tablets showed a AUC of 488.76 ∓ 175.00 ng.,[Pharmacokinetic study of a new chewing gum dextromethorphan delivery system]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21269969/),∓,488.76,266101,DB00514,Dextromethorphan
,21269969,C(max),"ml(-1).h, C(max) of 95.45 ∓ 17.53 ng/ml, and t(max) of 1.83 ∓ 0.57 h as compared with the corresponding parameters of 370.13 ∓ 90.56 ng.",[Pharmacokinetic study of a new chewing gum dextromethorphan delivery system]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21269969/),∓,95.45,266102,DB00514,Dextromethorphan
,21269969,C(max),"ml(-1).h, C(max) of 95.45 ∓ 17.53 ng/ml, and t(max) of 1.83 ∓ 0.57 h as compared with the corresponding parameters of 370.13 ∓ 90.56 ng.",[Pharmacokinetic study of a new chewing gum dextromethorphan delivery system]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21269969/),[ng] / [ml],17.53,266103,DB00514,Dextromethorphan
,21269969,t(max),"ml(-1).h, C(max) of 95.45 ∓ 17.53 ng/ml, and t(max) of 1.83 ∓ 0.57 h as compared with the corresponding parameters of 370.13 ∓ 90.56 ng.",[Pharmacokinetic study of a new chewing gum dextromethorphan delivery system]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21269969/),∓,1.83,266104,DB00514,Dextromethorphan
,21269969,relative bioavailability,The relative bioavailability of the new chewing gum medicine system was (140.73 ∓ 65.91)%.,[Pharmacokinetic study of a new chewing gum dextromethorphan delivery system]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21269969/),%,140.73,266105,DB00514,Dextromethorphan
,8951188,Cmax,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[ng] / [ml],89,266260,DB00514,Dextromethorphan
,8951188,Cmax,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[ng] / [ml],44,266261,DB00514,Dextromethorphan
,8951188,AUC,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],1642,266262,DB00514,Dextromethorphan
,8951188,AUC,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],412,266263,DB00514,Dextromethorphan
,8951188,elimination half-life,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),h,6.1,266264,DB00514,Dextromethorphan
,8951188,elimination half-life,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),h,16.4,266265,DB00514,Dextromethorphan
,8951188,steady state Cmax,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[ng] / [ml],182,266266,DB00514,Dextromethorphan
,8951188,steady state Cmax,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],1706,266267,DB00514,Dextromethorphan
,8951188,steady state Cmax,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[ng] / [ml],49.6,266268,DB00514,Dextromethorphan
,8951188,AUC,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],1706,266269,DB00514,Dextromethorphan
,8951188,AUC,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],182,266270,DB00514,Dextromethorphan
,27306429,flow rate,"Chromatographic separation was achieved with methanol-water-formic acid (70:30:0.1% v/v/v) pumped at a flow rate of 0.3mL/min and a C18 column (50 × 2.1 mm i.d., 1.7 μm particle size) with a total run time of 5 min.",Quantification of lipid modified estrogenic derivative (ESC8) in rat plasma by LC-MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27306429/),[ml] / [min],0.3,267693,DB00514,Dextromethorphan
,27306429,total run time,"Chromatographic separation was achieved with methanol-water-formic acid (70:30:0.1% v/v/v) pumped at a flow rate of 0.3mL/min and a C18 column (50 × 2.1 mm i.d., 1.7 μm particle size) with a total run time of 5 min.",Quantification of lipid modified estrogenic derivative (ESC8) in rat plasma by LC-MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27306429/),min,5,267694,DB00514,Dextromethorphan
,27306429,m/z ions,"The m/z ions monitored were 568.5 and 272.1 for ESC8 and IS, respectively.",Quantification of lipid modified estrogenic derivative (ESC8) in rat plasma by LC-MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27306429/),,568.5,267695,DB00514,Dextromethorphan
,27306429,m/z ions,"The m/z ions monitored were 568.5 and 272.1 for ESC8 and IS, respectively.",Quantification of lipid modified estrogenic derivative (ESC8) in rat plasma by LC-MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27306429/),,272.1,267696,DB00514,Dextromethorphan
,27306429,peak concentration,"The peak concentration of ESC8 was found to be 110.72 ng/mL, the area under the concentration-time curve was 1625.23ng/mL h and the half-life was 11.72 h.",Quantification of lipid modified estrogenic derivative (ESC8) in rat plasma by LC-MS: application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27306429/),[ng] / [ml],110.72,267697,DB00514,Dextromethorphan
,27306429,area under the concentration-time curve,"The peak concentration of ESC8 was found to be 110.72 ng/mL, the area under the concentration-time curve was 1625.23ng/mL h and the half-life was 11.72 h.",Quantification of lipid modified estrogenic derivative (ESC8) in rat plasma by LC-MS: application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27306429/),[ng] / [h·ml],1625.23,267698,DB00514,Dextromethorphan
,27306429,half-life,"The peak concentration of ESC8 was found to be 110.72 ng/mL, the area under the concentration-time curve was 1625.23ng/mL h and the half-life was 11.72 h.",Quantification of lipid modified estrogenic derivative (ESC8) in rat plasma by LC-MS: application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27306429/),h,11.72,267699,DB00514,Dextromethorphan
,27771456,Cmax,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],79.44 to 29.96,268837,DB00514,Dextromethorphan
,27771456,Cmax,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],151,268838,DB00514,Dextromethorphan
,27771456,AUCall,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],167.27 to 62.25,268839,DB00514,Dextromethorphan
,27771456,AUCall,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],347.68 to 223.24,268840,DB00514,Dextromethorphan
,27771456,AUCinf,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],183.39 to 84.76,268841,DB00514,Dextromethorphan
,27771456,AUCinf,"After being pretreated with AF in rats, the plasma concentrations of dextrorphan and hydroxymetoprolol significantly decreased, with Cmax going from 79.44 to 29.96 and 151.18 to 83.39hng/mL (P<0.05), AUCall from 167.27 to 62.25 and 347.68 to 223.24hng/mL (P<0.05), and AUCinf from 183.39 to 84.76 and 350.59 to 234.57hng/mL (P<0.05), respectively, in comparison with those of untreated rats.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[hng] / [ml],350.59 to 234.57,268842,DB00514,Dextromethorphan
,27771456,t1/2,The t1/2 of hydroxymetoprolol significantly increased from 1.14 to 1.99h (P<0.05).,Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),h,1.14,268843,DB00514,Dextromethorphan
,27771456,t1/2,The t1/2 of hydroxymetoprolol significantly increased from 1.14 to 1.99h (P<0.05).,Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),h,1.99,268844,DB00514,Dextromethorphan
,27771456,apparent Ki,"The in vitro incubation test showed that AF competitively inhibited the CYP2D6, with apparent Ki value of 0.64µg/mL.",Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771456/),[μg] / [ml],0.64,268845,DB00514,Dextromethorphan
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,13.00,270253,DB00514,Dextromethorphan
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,25.83,270254,DB00514,Dextromethorphan
,2266495,clearance,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),[ml] / [kg·min],4.8,272317,DB00514,Dextromethorphan
,2266495,clearance,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),[ml] / [kg·min],3.3,272318,DB00514,Dextromethorphan
,2266495,mean residence time,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),min,606,272319,DB00514,Dextromethorphan
,2266495,mean residence time,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),min,1361,272320,DB00514,Dextromethorphan
,2266495,systemic availability,The systemic availability of subcutaneous CsA was close to 100%.,Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),%,100,272321,DB00514,Dextromethorphan
,2266495,steady state CsA concentrations,The steady state CsA concentrations assessed by HPLC in whole blood after subcutaneous dosing of 20 mg/kg per day for 23 days (n = 10) were about 1000 ng/ml in dark Agouti rats.,Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),[ng] / [ml],1000,272322,DB00514,Dextromethorphan
,21456632,C(max),"The mean ± SD C(max) of MDMA was 188.8 ± 16.7 ng/mL, with a time to reach C(max) (t(max)) of 2.0 ± 0.4 hours and an AUC from 0 to 25 hours of 2645.2 ± 170.9 mg · h/mL.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),[ng] / [ml],188.8,273634,DB00514,Dextromethorphan
,21456632,time to reach C(max) (t(max)),"The mean ± SD C(max) of MDMA was 188.8 ± 16.7 ng/mL, with a time to reach C(max) (t(max)) of 2.0 ± 0.4 hours and an AUC from 0 to 25 hours of 2645.2 ± 170.9 mg · h/mL.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),h,2.0,273635,DB00514,Dextromethorphan
,21456632,AUC from 0 to 25 hours,"The mean ± SD C(max) of MDMA was 188.8 ± 16.7 ng/mL, with a time to reach C(max) (t(max)) of 2.0 ± 0.4 hours and an AUC from 0 to 25 hours of 2645.2 ± 170.9 mg · h/mL.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),[h·mg] / [ml],2645.2,273636,DB00514,Dextromethorphan
,21456632,urinary recovery,The urinary recovery of the dextromethorphan dose as dextromethorphan and its main metabolites was 25.4 ± 8.9% with no MDMA pretreatment versus 6.6 ± 1.1% after 1.5 mg/kg of MDMA (p = 0.0001).,"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),%,25.4,273637,DB00514,Dextromethorphan
,21456632,urinary recovery,The urinary recovery of the dextromethorphan dose as dextromethorphan and its main metabolites was 25.4 ± 8.9% with no MDMA pretreatment versus 6.6 ± 1.1% after 1.5 mg/kg of MDMA (p = 0.0001).,"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),%,6.6,273638,DB00514,Dextromethorphan
,21456632,metabolic ratio (MR),"The metabolic ratio (MR) increased almost 60-fold from 0.018 ± 0.028 to 0.998 ± 0.932 after MDMA administration, with 100% of the subjects having a value greater than the antimode of 0.3 that signified the poor-metabolizer phenotype.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),,0.018,273639,DB00514,Dextromethorphan
,21456632,metabolic ratio (MR),"The metabolic ratio (MR) increased almost 60-fold from 0.018 ± 0.028 to 0.998 ± 0.932 after MDMA administration, with 100% of the subjects having a value greater than the antimode of 0.3 that signified the poor-metabolizer phenotype.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),,0.998,273640,DB00514,Dextromethorphan
,21456632,recovery half-life,"CYP2D6 activity recovered after 10 days to 90% of baseline activity, with a recovery half-life of 36.6 ± 22.9 hours.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),h,36.6,273641,DB00514,Dextromethorphan
,21456632,recovery half-life,Male subjects showed a shorter recovery half-life (27.6 ± 25.1 hours).,"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),h,27.6,273642,DB00514,Dextromethorphan
